We use cookies for a better user experience. Read our Privacy Policy

I Agree

Acute Exacerbation of CRS Treatment Market Outlook, 2021-2031

Acute Exacerbation of CRS Treatment Market (Treatment: Antibiotics, Leukotriene Inhibitors, Antihistamines, Mucolytics, Decongestants, Nasal Saline Irrigation, Oral Corticosteroids, Endoscopic Sinus Surgery, and Others; Route of Administration: Topical, Nasal, Oral, and Injectable; Distribution Channel: Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies; and Infection Type: Staphylococcus Species and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Manufacturers Increase Availability of Treatment Options amid COVID-19 Pandemic

Acute exacerbation of CRS (Chronic Rhinosinusitis) is regarded as a serious airway disease. According to the World Health Organization (WHO) recommendations, it may be a risk factor for exposure to COVID-19 as well as for existing COVID-19 positive patients. Hence, companies in the acute exacerbation of CRS treatment market are increasing the availability of treatments and medicines to reduce morbidity and mortality of patients.

Manufacturers in the acute exacerbation of CRS treatment market are boosting their production capacities in intranasal corticosteroids that are considered as the gold standard for CRS in patients with coronavirus. Stakeholders are gaining awareness about reducing surgical treatments to the minimum. Treatment with biologics is being recommended with careful monitoring in non-infected patients and should be temporarily interrupted during COVID-19 infection.

acute exacerbation of crs treatment market infographic

To know the scope of our report Get a Sample on Acute Exacerbation of CRS Treatment Market

Biologics Hold Promising Potentials for CRSwNP Patients Before Initial Surgery

CRS with nasal polyps (CRSwNP) is a common and heterogeneous inflammatory disease of the upper respiratory tract. Despite the potential value of biomarker-based endotyping to provide guidance regarding optimal care and treatment choices for patients with CRSwNP, the current practice is largely not biomarker-based. This explains why the acute exacerbation of CRS treatment market is slated to register a CAGR of 4.6% from 2021 to 2031. Hence, companies are now increasing focus on biologics, especially for patients before considering initial surgery.

Patients with comorbid severe asthma and for whom surgery is less available are opting for biologics. Biologics are being recommended for use immediately following surgery in patients who have a history of nasal polyp recurrence within 12 months of a prior surgery.

Get a glimpse of the in-depth analysis through our Report Brochure

Antibiotics Help in Treatment of Patients with Severe Asthma, CRS

Severe asthma and acute exacerbation of CRS lead to frequent comorbidities, thus complicating the overall management of the disease. Biomarkers such as absolute eosinophil count in peripheral blood and fractional exhaled nitric oxide (FeNO) may be used as indicators of type 2 asthma endotypes and help predict response to biologic therapies.

There is data indicating that the presence of CRS is associated with worse outcomes in patients with asthma, more specifically with increased risk of frequent exacerbations. Hence, companies in the acute exacerbation of CRS treatment market are increasing their production capabilities in antibiotics, oral analgesics, and intranasal steroids, among other treatment options to improve patient outcomes.

Individualized Treatment with Antibiotics Improves Patient Quality of Life

Defining acute exacerbations of CRS with quantifiable clinical and immunologic metrics has remained a challenge due to the complex etiology of acute exacerbations and the inconsistency in endpoint reporting. Current recommendations for treatment of acute exacerbation of CRS continue to suggest blanket medical intervention, including short-course antibiotic treatment. Companies in the acute exacerbation of CRS treatment market are increasing R&D to improve methods for clinically defining the disease and its risk factors to facilitate individualized treatment.

Manufacturers in the acute exacerbation of CRS treatment market are boosting their output capacities in first-line antibiotic therapies such as amoxicillin, with or without clavulanate to improve patient quality of life.

acute exacerbation of crs treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Healthcare providers are closely monitoring the COVID-19 situation and have recommended aligning any diagnostic and treatment operations with guidance from the WHO and Centers for Disease Control and Prevention (CDC). The acute exacerbation of CRS treatment market is expected to reach US$ 7.06 Bn by 2031. Though available biological agents have therapeutic effects for patients with asthma and CRS, the improvement of nasal symptoms is less evident, despite reaching satisfactory asthma control. Hence, companies should improve their knowledge in potential therapeutic agents and increase the ability of biological agents to equally reach different tissues in order to improve patient outcomes.

Acute Exacerbation of CRS Treatment Market: Overview

  • Rhinosinusitis is a serious health issue that affects people all over the world. It's a sinus infection that starts in the nasal passages and spreads to the paranasal sinuses. Nasal blockage, purulent nasal discharge, and face pain-pressure-fullness are the three main symptoms. The patient defines nasal obstruction as obstruction, congestion, blockage, or stuffiness; purulent nasal discharge is hazy or colored in appearance; and facial pain-pressure-fullness affects the anterior face and periorbital area, or presents as headache that can be localized or widespread.
  • The acute exacerbation of CRS treatment market is anticipated to be driven by the increase in rhinosinusitis patients during the forecast period. In 2018, the CDC estimated that 28.9 million individuals in the U.S. were diagnosed with rhinosinusitis.

Acute Exacerbation of CRS Treatment: Market Drivers

  • Acute CRS exacerbation is gaining traction due of its considerable impact on patients' quality of life and healthcare costs. Acute CRS exacerbation is a kind of CRS that is started by viruses and subsequently followed by bacterial infections, which may be the result of a bacterial species imbalance inside the sinus cavities.
  • Understanding the etiology and immunological mechanisms of acute CRS exacerbation has increased significantly. However, there is currently no consensus definition, diagnostic criteria, biomarkers to distinguish acute CRS exacerbation from CRS, illness severity assessment, or evidence-based therapy choices for acute CRS exacerbation.
  • Rise in mucosal inflammation incidences leading to rhinosinusitis is expected to drive the demand for acute CRS exacerbation treatment over the next few years
  • Demand for acute CRS exacerbation treatment is expected to further increase due to rise in patient awareness about sinusitis treatment. New products and device development in the field of acute CRS exacerbation are also projected to significantly propel the market.

Surge in Product Launches and Approvals

  • In December 2020, AstraZeneca announced gaining marketing authorization from the Drugs Controller General of India (DCGI) for use of the original research medicine, Fasenra (Benralizumab solution, for injection in a single dose prefilled syringe30 mg/ml subcutaneous administration only) in patients with severe asthma (eosinophilic asthma) or chronic rhinosinusitis. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients or patients with chronic rhinosinusitis. Rising number of product approvals is expected to drive the market during the forecast period.

Market Segmentation: Acute Exacerbation of CRS Treatment Market

  • In terms of treatment, the global acute exacerbation of CRS treatment market has been classified into antibiotics, leukotriene inhibitors, antihistamines, mucolytics, decongestants, nasal saline irrigation, oral corticosteroids, endoscopic sinus surgery, and others
  • In terms of route of administration, the global acute exacerbation of CRS treatment market has been segregated into topical, nasal, oral, and injectable
  • Based on distribution channel, the global acute exacerbation of CRS treatment market has been categorized into online pharmacies, retail pharmacies, and hospital pharmacies
  • Based on infection type, the global acute exacerbation of CRS treatment market has been bifurcated into staphylococcus species and others
  • Each of the segments has been analyzed in detail for acute exacerbation of CRS treatment trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The acute exacerbation of CRS treatment market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: Acute Exacerbation of CRS Treatment Market

  • In terms of region, the global acute exacerbation of CRS treatment market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
  • North America accounted for a prominent share of the global market for acute exacerbation of CRS treatment in 2020. North America is expected to retain its market share during the forecast period primarily due to rise in cases of rhinosinusitis in the U.S. For instance, rhinosinusitis accounted for around 12 to 17 million annual visits to physicians and 12% of antibiotics prescribed to geriatric patients in the U.S., making it one of the 10 most common conditions to be treated in ambulatory practice. Hence, increase in cases of acute rhinosinusitis is projected to fuel the global acute exacerbation of CRS treatment market.
  • Asia Pacific is likely to increase its market share by the end of the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by local players, especially in China and India, are anticipated to drive the acute exacerbation of CRS treatment market in the region. Surge in healthcare expenditure and rise in awareness about sinusitis are projected to drive the market in the region.
  • Demand for acute exacerbation of CRS treatment is also driven by expansion of major industries and the launch of acute exacerbation of CRS treatment by major companies in the region
  • Current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2017 to 2031, along with their CAGRs for the period from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which are estimated to help new companies willing to enter the market and existing companies to increase market share and in the decision-making process.

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the global acute exacerbation of CRS treatment market
  • Leading players analyzed in the report are
    • Sun Pharmaceutical Industries, Inc.
    • Pfizer Inc.
    • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
    • Fresenius Kabi USA, LLC
    • Dr. Reddy's Laboratories, Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Abbott Laboratories
    • Bayer AG
    • Eli Lilly And Company
    • Bristol-Myers Squibb
    • Merck & Co, Inc.
    • AstraZeneca Plc
    • Amneal Pharmaceuticals LLC
    • GlaxoSmithKline plc.
    • Aurobindo Pharma
    • Hikma Pharmaceuticals plc
    • Wockhardt
    • Mylan N.V.
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Acute Exacerbation of CRS Treatment Market – Segmentation

TMR’s study on the global acute exacerbation of CRS treatment market includes information divided into four segments: treatment, route of administration, distribution channel, infection type, and region.       

Treatment
  • Antibiotics
  • Leukotriene Inhibitors
  • Antihistamines
  • Mucolytics
  • Decongestants
  • Nasal Saline Irrigation
  • Oral Corticosteroids
  • Endoscopic sinus surgery
  • Others
Route of Administration
  • Topical
  • Nasal
  • Oral
  • Injectable
Distribution Channel
  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies
Infection Type
  • Staphylococcus Species
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Changing industry trends and other crucial market dynamics associated with these segments of the global acute exacerbation of CRS treatment market have been discussed in detail. 

Acute Exacerbation of CRS Treatment Market Outlook, 2021-2031

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of acute exacerbation of CRS treatment market?

Acute exacerbation of CRS treatment market to reach valuation of US$ 7.06 bn by 2031

What is the anticipated CAGR of the acute exacerbation of CRS treatment market in the forecast period?

Acute exacerbation of CRS treatment market is projected to expand at a CAGR of 4.6% from 2021 to 2031

What are the key driving factors for the growth of the acute exacerbation of CRS treatment market?

Acute exacerbation of CRS treatment market is driven by increase in instances of rhinosinusitis

Which region is expected to project the highest market share in the global acute exacerbation of CRS treatment market?

North America dominated the global acute exacerbation of CRS treatment market and the trend is anticipated to continue during the forecast period

Who are the key players in the global acute exacerbation of CRS treatment market?

Key players in the global acute exacerbation of CRS treatment market include Sun Pharmaceutical Industries, Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Exacerbation of CRS Treatment Market

4. Market Overview

    4.1. Introduction & Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunities

    4.3. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, 2017–2031

5. Market Outlook

    5.1. Clinical Trials & Regulatory Approvals Analysis

    5.2. List of Brand / Product Approved

    5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

    5.4. Technological Advancements

    5.5. Disease Prevalence & Incidence

6. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Treatment

    6.1. Introduction & Definition

    6.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        6.2.1. Acute Exacerbation of CRS

            6.2.1.1. Antibiotics

            6.2.1.2. Leukotriene Inhibitors

            6.2.1.3. Antihistamines

            6.2.1.4. Mucolytics

            6.2.1.5. Decongestants

            6.2.1.6. Nasal Saline Irrigation

            6.2.1.7. Oral Corticosteroids

            6.2.1.8. Endoscopic sinus surgery

            6.2.1.9. Others

    6.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Route of Administration

7. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Route of Administration

    7.1. Introduction & Definition

    7.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration2017–2031 

        7.2.1. Acute Exacerbation of CRS

            7.2.1.1. Topical

            7.2.1.2. Nasal

            7.2.1.3. Oral

            7.2.1.4. Injectable   

    7.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Route of Administration

8. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        8.2.1. Acute Exacerbation of CRS   

            8.2.1.1. Online Pharmacies

            8.2.1.2. Retail Pharmacies

            8.2.1.3. Hospital Pharmacies         

    8.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Distribution Channel

9. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Infection Type

    9.1. Introduction & Definition

    9.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

        9.2.1. Acute Exacerbation of CRS   

            9.2.1.1. Staphylococcus Species

            9.2.1.2. Others

    9.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Infection Type

10. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Region

11. North America Acute Exacerbation of CRS Treatment Market Analysis and Forecast

    11.1. Introduction

    11.2. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        11.2.1. Acute Exacerbation of CRS

            11.2.1.1. Antibiotics

            11.2.1.2. Leukotriene Inhibitors

            11.2.1.3. Antihistamines

            11.2.1.4. Mucolytics

            11.2.1.5. Decongestants

            11.2.1.6. Nasal Saline Irrigation

            11.2.1.7. Oral Corticosteroids

            11.2.1.8. Endoscopic sinus surgery

            11.2.1.9. Others 

    11.3. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

        11.3.1. Acute Exacerbation of CRS

            11.3.1.1. Topical

            11.3.1.2. Nasal

            11.3.1.3. Oral

            11.3.1.4. Injectable 

    11.4. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        11.4.1. Acute Exacerbation of CRS

            11.4.1.1. Online Pharmacies

            11.4.1.2. Retail Pharmacies

            11.4.1.3. Hospital Pharmacies 

    11.5. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

        11.5.1. Acute Exacerbation of CRS

            11.5.1.1. Staphylococcus Species

            11.5.1.2. Others   

    11.6. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Acute Exacerbation of CRS Treatment Market Attractiveness Analysis

        11.7.1. By Treatment

        11.7.2. By Route of Administration

        11.7.3. By Distribution Channel

        11.7.4. Infection Type   

        11.7.5. By Country

12. Europe Acute Exacerbation of CRS Treatment Market Analysis and Forecast

    12.1. Introduction

    12.2. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        12.2.1. Acute Exacerbation of CRS

            12.2.1.1. Antibiotics

            12.2.1.2. Leukotriene Inhibitors

            12.2.1.3. Antihistamines

            12.2.1.4. Mucolytics

            12.2.1.5. Decongestants

            12.2.1.6. Nasal Saline Irrigation

            12.2.1.7. Oral Corticosteroids

            12.2.1.8. Endoscopic sinus surgery

            12.2.1.9. Others   

    12.3. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

        12.3.1. Acute Exacerbation of CRS

            12.3.1.1. Topical

            12.3.1.2. Nasal

            12.3.1.3. Oral

            12.3.1.4. Injectable

    12.4. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        12.4.1. Acute Exacerbation of CRS

            12.4.1.1. Staphylococcus Species

            12.4.1.2. Others 

    12.5. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        12.5.1. Germany

        12.5.2. U.K.

        12.5.3. France

        12.5.4. Spain

        12.5.5. Italy

        12.5.6. Rest of Europe

    12.6. Europe Acute Exacerbation of CRS Treatment Market Attractiveness Analysis

        12.6.1. By Treatment

        12.6.2. By Route of Administration

        12.6.3. By Distribution Channel

        12.6.4. By Infection Type

        12.6.5. By Country/Sub-region

13. Asia Pacific Acute Exacerbation of CRS Treatment Market Analysis and Forecast

    13.1. Introduction

    13.2. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        13.2.1. Acute Exacerbation of CRS

            13.2.1.1. Antibiotics

            13.2.1.2. Leukotriene Inhibitors

            13.2.1.3. Antihistamines

            13.2.1.4. Mucolytics

            13.2.1.5. Decongestants

            13.2.1.6. Nasal Saline Irrigation

            13.2.1.7. Oral Corticosteroids

            13.2.1.8. Endoscopic sinus surgery

            13.2.1.9. Others

    13.3. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

        13.3.1. Acute Exacerbation of CRS

            13.3.1.1. Topical

            13.3.1.2. Nasal

            13.3.1.3. Oral

            13.3.1.4. Injectable 

    13.4. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        13.4.1. Acute Exacerbation of CRS

            13.4.1.1. Online Pharmacies

            13.4.1.2. Retail Pharmacies

            13.4.1.3. Hospital Pharmacies

    13.5. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        13.5.1. China

        13.5.2. Japan

        13.5.3. India

        13.5.4. Australia & New Zealand

        13.5.5. Rest of Asia Pacific

    13.6. Asia Pacific Acute Exacerbation of CRS Treatment Market Attractiveness Analysis

        13.6.1. By Treatment

        13.6.2. By Route of Administration

        13.6.3. By Distribution Channel

        13.6.4. Infection Type

        13.6.5. By Country/Sub-region

14. Latin America Acute Exacerbation of CRS Treatment Market Analysis and Forecast

    14.1. Introduction

    14.2. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        14.2.1. Acute Exacerbation of CRS

            14.2.1.1. Antibiotics

            14.2.1.2. Leukotriene Inhibitors

            14.2.1.3. Antihistamines

            14.2.1.4. Mucolytics

            14.2.1.5. Decongestants

            14.2.1.6. Nasal Saline Irrigation

            14.2.1.7. Oral Corticosteroids

            14.2.1.8. Endoscopic sinus surgery

            14.2.1.9. Others

    14.3. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

        14.3.1. Acute Exacerbation of CRS

            14.3.1.1. Topical

            14.3.1.2. Nasal

            14.3.1.3. Oral

            14.3.1.4. Injectable

    14.4. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        14.4.1. Acute Exacerbation of CRS

            14.4.1.1. Online Pharmacies

            14.4.1.2. Retail Pharmacies

            14.4.1.3. Hospital Pharmacies

    14.5. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        14.5.1. Brazil

        14.5.2. Mexico

        14.5.3. Rest of Latin America

    14.6. Latin America Acute Exacerbation of CRS Treatment Market Attractiveness Analysis

        14.6.1. By Treatment

        14.6.2. By Route of Administration

        14.6.3. By Distribution Channel

        14.6.4. Infection Type

        14.6.5. By Country/Sub-region

15. Middle East & Africa Acute Exacerbation of CRS Treatment Market Analysis and Forecast

    15.1. Introduction

    15.2. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        15.2.1. Acute Exacerbation of CRS

            15.2.1.1. Antibiotics

            15.2.1.2. Leukotriene Inhibitors

            15.2.1.3. Antihistamines

            15.2.1.4. Mucolytics

            15.2.1.5. Decongestants

            15.2.1.6. Nasal Saline Irrigation

            15.2.1.7. Oral Corticosteroids

            15.2.1.8. Endoscopic sinus surgery

            15.2.1.9. Others

    15.3. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

        15.3.1. Acute Exacerbation of CRS

            15.3.1.1. Topical

            15.3.1.2. Nasal

            15.3.1.3. Oral

            15.3.1.4. Injectable

    15.4. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        15.4.1. Acute Exacerbation of CRS

            15.4.1.1. Online Pharmacies

            15.4.1.2. Retail Pharmacies

            15.4.1.3. Hospital Pharmacies

    15.5. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

        15.5.1. Acute Exacerbation of CRS

            15.5.1.1. Staphylococcus Species

            15.5.1.2. Others

    15.6. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Middle East & Africa Acute Exacerbation of CRS Treatment Market Attractiveness Analysis

        15.7.1. By Treatment

        15.7.2. By Route of Administration

        15.7.3. By Distribution Channel

        15.7.4. By Infection Type

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Position Analysis, by Company, 2020

    16.2. Company Profiles

        16.2.1. Sun Pharmaceutical Industries, Inc.

            16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.1.2. Growth Strategies

            16.2.1.3. SWOT Analysis

        16.2.2. Pfizer Inc.

            16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2.2. Growth Strategies

            16.2.2.3. SWOT Analysis

        16.2.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

            16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.3.2. Growth Strategies

            16.2.3.3. SWOT Analysis

        16.2.4. Fresenius Kabi USA, LLC.

            16.2.4.1. Company Overview (HQ, Business Segments)

            16.2.4.2. Growth Strategies

            16.2.4.3. SWOT Analysis

        16.2.5. Dr. Reddy's Laboratories, Inc.

            16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.5.2. Growth Strategies

            16.2.5.3. SWOT Analysis

        16.2.6. Novartis AG

            16.2.6.1. Company Overview (HQ, Business Segments)

            16.2.6.2. Growth Strategies

            16.2.6.3. SWOT Analysis

        16.2.7. Teva Pharmaceutical Industries Ltd

            16.2.7.1. Company Overview (HQ, Business Segments)

            16.2.7.2. Growth Strategies

            16.2.7.3. SWOT Analysis

        16.2.8. Sanofi

            16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.8.2. Growth Strategies

            16.2.8.3. SWOT Analysis

        16.2.9. Abbott Laboratories

            16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.9.2. Growth Strategies

            16.2.9.3. SWOT Analysis

        16.2.10. Bayer AG

            16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.10.2. Growth Strategies

            16.2.10.3. SWOT Analysis

        16.2.11. Eli Lilly And Company

            16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.11.2. Growth Strategies

            16.2.11.3. SWOT Analysis

        16.2.12. Bristol-Myers Squibb

            16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.12.2. Growth Strategies

            16.2.12.3. SWOT Analysis

        16.2.13. Merck & Co, Inc.

            16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.13.2. Growth Strategies

            16.2.13.3. SWOT Analysis

        16.2.14. AstraZeneca Plc

            16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.14.2. Growth Strategies

            16.2.14.3. SWOT Analysis

        16.2.15. Amneal Pharmaceuticals LLC

            16.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.15.2. Growth Strategies

            16.2.15.3. SWOT Analysis

        16.2.16. GlaxoSmithKline plc.

            16.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.16.2. Growth Strategies

            16.2.16.3. SWOT Analysis

        16.2.17. Aurobindo Pharma

            16.2.17.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.17.2. Growth Strategies

            16.2.17.3. SWOT Analysis

        16.2.18. Hikma Pharmaceuticals plc

            16.2.18.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.18.2. Growth Strategies

            16.2.18.3. SWOT Analysis

        16.2.19. Wockhardt

            16.2.19.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.19.2. Growth Strategies

            16.2.19.3. SWOT Analysis

        16.2.20. Mylan N.V. 

            16.2.20.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.20.2. Growth Strategies

            16.2.20.3. SWOT Analysis  

List of Tables

Table 01: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 02: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

Table 03: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 04: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 05: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

Table 06: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 07: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 08: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 09: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

Table 10: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 11: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 12: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

Table 13: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 15: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

Table 16: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 17: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 18: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

Table 19: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 21: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

Table 22: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 23: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 24: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

Table 25: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 27: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

Table 28: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 29: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 30: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

Table 31: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 32: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 33: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

Table 34: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 35: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 36: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

List of Figures

Figure 01: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 03: Global Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 04: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Antibiotics, 2017–2031

Figure 05: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Leukotriene Inhibitors, 2017–2031

Figure 06: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Antihistamines, 2017–2031

Figure 07: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Mucolytics, 2017–2031

Figure 08: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Decongestants, 2017–2031

Figure 09: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Nasal Saline Irrigation, 2017–2031

Figure 10: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Oral Corticosteroids, 2017–2031

Figure 11: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Endoscopic Sinus Surgery, 2017–2031

Figure 12: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Others, 2017–2031

Figure 13: Global Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 14: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 15: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Topical, 2017–2031

Figure 16: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Nasal, 2017–2031

Figure 17: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Oral, 2017–2031

Figure 18: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Injectable, 2017–2031

Figure 19: Global Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 20: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 21: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Online Pharmacies, 2017-2031

Figure 22: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Retail Pharmacies, 2017-2031

Figure 23: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Online Pharmacies, 2017-2031

Figure 24: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Retail Pharmacies, 2017-2031

Figure 25: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Hospital Pharmacies, 2017-2031

Figure 26: Global Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031

Figure 27: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031

Figure 28: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Staphylococcus Species, 2017–2031

Figure 29: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Others, 2017–2031

Figure 30: Global Acute Exacerbation of CRS Market Value Share Analysis, by Region, 2020 and 2031

Figure 31: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Region, 2021–2031

Figure 32: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 33: North America Acute Exacerbation of CRS Market Value Share, by Country, 2020 and 2031

Figure 34: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Country, 2021–2031

Figure 35: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 36: North America Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 37: North America Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 38: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 39: North America Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 40: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 41: North America Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031

Figure 42: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031

Figure 43: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 44: Europe Acute Exacerbation of CRS Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 45: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 46: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 47: Europe Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 48: Europe Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 49: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 50: Europe Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 51: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 52: Europe Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031

Figure 53: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031

Figure 54: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 55: Asia Pacific Acute Exacerbation of CRS Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 56: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 57: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 58: Asia Pacific Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 59: Asia Pacific Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 60: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 61: Asia Pacific Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 62: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 63: Asia Pacific Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031

Figure 64: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031

Figure 65: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 66: Latin America Acute Exacerbation of CRS Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 67: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 68: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 69: Latin America Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 70: Latin America Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 71: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 72: Latin America Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 73: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 74: Latin America Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031

Figure 75: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031

Figure 76: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 77: Middle East & Africa Acute Exacerbation of CRS Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 78: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 79: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 80: Middle East & Africa Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 81: Middle East & Africa Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 82: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 83: Middle East & Africa Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 84: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 85: Middle East & Africa Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031

Figure 86: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

176

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved